Edwards Lifesciences rises sharply following court action, upgrades The stock is up 13.6% to $82.97 following a U.S. District Court preliminary injunction that limits sales of Medtronic's (MDT) CoreValve system in the United States. JPMorgan and CRT Capital upgraded the name to Neutral and Buy, respectively. Wells Fargo upped its price target to $90 to $91. At current price the next major resistance level is at $86.11, the 52-week high. Support is at $81.93, the opening price of the day.